Showing 7261-7270 of 9550 results for "".
- Melanoma Cells Grow More Aggressive with Agehttps://practicaldermatology.com/news/melanoma-cells-grow-more-aggressive-with-age/2458622/Aged tumor cells in melanoma tend to be metastatic and more resistant to treatment compared with younger tumor cells, according to an international team led by researchers out of The Wistar Institute in Philadelphia. The findings, which appear in
- Rosacea Awareness Month Highlights Potential Increased Health Riskshttps://practicaldermatology.com/news/rosacea-awareness-month-highlights-potential-increased-health-risks/2458624/New studies are now revealing potential associations between rosacea and increased risks of cardiovascular disease, gastrointestinal disease, certain types of cancer and many other systemic illnesses. The National Rosacea Society (NRS) has designated April as Rosacea Awareness Month to alert the
- Next Stop FDA Approval? Dupilumab Improves Symptoms in Moderate-to-Severe ADhttps://practicaldermatology.com/news/next-stop-fda-approval-dupilumab-improves-symptoms-in-moderate-to-severe-ad/2458625/Dupilumab helps improve the signs and symptoms of moderate-to-severe atopic dermatitis (AD) in adults, according to two late stage clinical trials. The U.S. Food and Drug Administration (FDA) granted dupilumab Breakthrough Therapy designation in AD in November 2014. U.S. regulatory
- Tissue Regeneration Leader Takes Home 2016 Furumoto Award at ASLMS 2016https://practicaldermatology.com/news/tissue-regeneration-leader-takes-home-2016-furumoto-award-at-aslms-2016/2458627/Praveen Arany, DDS, PhD will receive the 2016 ASLMS Dr. Horace Furumoto Innovations Young Investigator Award during the Plenary Session at ASLMS 2016, the Annual Conference of the American Society for Laser Medicine & Surgery, Inc. (ASLMS).
- North America's Scar Treatment Poised for Growth Spurt by 2022https://practicaldermatology.com/news/north-america-scar-treatment-market-set-to-grow-by-2022/2458629/Scar treatment will be a hot growth area in coming years, according to a new report by Persistence Market Research. The report cites a rising incidence of burn and trauma cases and an increasing preval
- Vitals Report: National Average Wait Time Down Nearly 10% since 2009https://practicaldermatology.com/news/vitals-report-national-average-wait-time-down-nearly-10-since-2009/2458630/When it comes to waiting for a doctor’s appointment, most patients are waiting 19 minutes, 19 seconds, according to Vitals 7th annual wait time report This is down nearly 10 percent from the average 21 minutes and 18 seconds patients once sp
- Let the Sun Shine In? Research Reveals Why Sunbathers May Live Longer than Sun Avoidershttps://practicaldermatology.com/news/let-the-sun-shine-in-research-reveals-why-sunbathers-may-live-longer-than-sun-avoiders/2458634/Sunbathers tend to live longer than their shade-seeking counterparts despite their increased risk for skin cancer, but why? New research suggests that a decrease in heart disease and noncancer/non-heart disease deaths may explain the paradox.
- Vitae Achieves Proof-of-Concept with First-in-Class RORyt Inhibitor for Psoriasishttps://practicaldermatology.com/news/vitae-achieves-proof-of-concept-with-first-in-class-roryt-inhibitor-for-psoriasis/2458643/Vitae Pharmaceuticals, Inc. shared positive top-line results from its Phase 2a proof-of-concept clinical trial of VTP-43742 in psoriatic patients. VTP-43742 is Vitae's wholly owned, first-in-class, orally active RORγt inhibitor with the potential to transform the treatment of multiple a
- Bernie Sanders Urges Treasury to Block Pfizer-AGN Mergerhttps://practicaldermatology.com/news/bernie-sanders-urges-treasury-to-block-pfizer-agn-merger/2458642/Democratic presidential hopeful Bernie Sanders is urging the US Treasury to prevent the Pfizer-Allergan deal, according to media reports. Calling it a ‘tax scam” in a
- Do the FDA's Proposed Regulations on Tanning Bed Use Go Far Enough?https://practicaldermatology.com/news/do-the-fdas-proposed-regulations-on-tanning-bed-use-go-far-enough/2458646/As the comment period on the US Food and Drug Administration’s proposal to restrict tanning bed use winds down, researchers are weighing in on the proposal's merits and potential shortfalls. Investigators